REGENCY: Obinutuzumab’s Promise for Lupus Nephritis
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
REGENCY: Obinutuzumab’s Promise for Lupus Nephritis
-
Narrated by:
-
By:
About this listen
Join Dr Raquel Faria and Professors Richard Furie and Maria Dall’Era as they discuss the results of the phase 3 REGENCY trial of obinutuzumab for the treatment of lupus nephritis.This episode explores what obinutuzumab could mean for the future management of lupus nephritis.
Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines forpatients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet